77 results
8-K
EX-99.2
IMNM
Immunome, Inc.
13 Feb 24
Results of Operations and Financial Condition
4:10pm
to outweigh potential benefits;
external factors such as an epidemic or pandemic which prevent execution of the study(ies) or recruitment of subjects … , fire, explosion, extreme weather condition, medical epidemics, including any potential effects from a pandemic, such as the COVID-19 pandemic, power
8-K
EX-2.1
xdvxco9syqb6n
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
424B3
ukjrqxivqls p0bd
28 Aug 23
Prospectus supplement
9:10am
S-4/A
j7b7bn
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
7amp9czvdaj8zmxmv
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
S-4
EX-10.42
9rozhe5
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
S-4
EX-10.43
i6jq3vulz4mrhayx5c8
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-2.1
25pmj2bq9i3cvjtfhkc
29 Jun 23
Business combination disclosure
9:10am
8-K
EX-2.1
fkm24
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
PRE 14A
5frq7jltw
7 Apr 23
Preliminary proxy
6:29am
8-K
EX-99.1
rhf6phnchrb0vf
15 Nov 22
Other Events
4:17pm
8-K
EX-99.1
oa0658 k8bajimvk
14 Nov 22
Immunome Reports Third Quarter 2022 Financial Results
9:06am